6--pterin | 59040-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 6--pterin
• 英文别名: pteroic acid methylamide；4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]-N-methylbenzamide
• CAS: 59040-25-4
• 化学式: C₁₅H₁₅N₇O₂
• 分子量: 325.33
• InChiKey: VGMWQSRCEWBGMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• [EN] MODIFIED IMMUNE CELLS AND USES THEREOF<br/>[FR] CELLULES IMMUNITAIRES MODIFIÉES ET LEURS UTILISATIONS
  申请人：ISI LIFE SCIENCES INC

  公开号：WO2019051317A1

  公开（公告）日：2019-03-14

  Disclosed are modified T-cells so that the modified T-cells are capable of penetrating the fugetactic wall generated by tumors, including solid mass tumors, as well as imparting tumor specific targeting for these modified T-cells.

  揭示了经过改良的T细胞，使这些改良的T细胞能够穿透肿瘤产生的浸润壁，包括固体肿瘤，同时为这些改良的T细胞赋予肿瘤特异性靶向。
• NANOPARTICLE AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT
  申请人：Wang Yun-Ming

  公开号：US20110092672A1

  公开（公告）日：2011-04-21

  A nanoparticle contains a core including superparamagnetic nanoparticles and having an outer surface, and siloxanyl moieties covalently coupled to the outer surface of the core and having Formula (I): In formula (I): X 1 and X 2 independently represent methylene, ethylene or propylene; R represents an optionally substituted pyridyl group, or —S—R is a group derived from a targeting ligand containing —SH group and effective to bind specifically with a predetermined targeted cell in an object; n and m independently represent an integer ranging from 1 to 3; and p represents an integer ranging from 9 to 45. The nanoparticles are suitable for use as a magnetic resonance imaging contrast agent.

  一种纳米颗粒包含一个核心，包括超顺磁性纳米颗粒，并具有外表面，以及共价结合到核心外表面的硅氧烷基团，具有化学式（I）：在化学式（I）中：X1和X2独立表示亚甲基、乙烯或丙烯基；R表示一个可选择取代的吡啶基，或者—S—R是从含有—SH基团并能够与目标对象中的特定靶细胞结合的靶向配体衍生的基团；n和m独立地表示从1到3的整数；p表示从9到45的整数。这些纳米颗粒适用于用作磁共振成像对比剂。
• CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS
  申请人：Leamon Christopher Paul

  公开号：US20100323973A1

  公开（公告）日：2010-12-23

  Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.

  本文描述了一种使用细胞受体结合药物递送共轭物质的组合物和方法，其中包含亲水性空间连接剂，用于成像、诊断和/或治疗由致病细胞群体引起的疾病和疾病状态的靶向药物递送。
• TARGETING LIPIDS
  申请人：Arbutus Biopharma Corporation

  公开号：EP3156077A1

  公开（公告）日：2017-04-19

  The present invention provides targeting lipids of structure (Cl) L100 - linker - L101, where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or -CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

  本发明提供了结构为（Cl）L100-连接体-L101的靶向脂质，其中L100为脂质、亲脂质、烷基、烯基或炔基，L101为配体或- (O )pO(CH2)q -配体，p为1-1000，q为1-20。此外，本发明还提供了向细胞输送治疗剂的组合物和方法。其中特别包括新型脂质和核酸-脂质颗粒，它们能有效地封装核酸，并在体内将封装的核酸有效地递送到细胞中。
• Method of imaging with a chelating agent
  申请人：ENDOCYTE, INC.

  公开号：US10420850B2

  公开（公告）日：2019-09-24

  The present disclosure relates to a method for imaging cancer by administering to a patient a labeled chelating compound and an unlabeled chelating compound.

  本公开涉及一种通过向患者施用标记螯合化合物和未标记螯合化合物进行癌症成像的方法。